aspirin

ACC 2021 | HOST-EXAM: Clopidogrel vs AAS como monoterapia post DAPT en las angioplastias

ACC 2021 | HOST-EXAM: Clopidogrel vs ASA monotherapy post DAPT in PCI patients

Clopidogrel monotherapy after dual antiplatelet therapy (DAPT) was associated with reduced mortality, MI, stroke, and other events in patients receiving PCI compared against aspirin monotherapy (ASA). This information was provided by the Korean HOST-EXAM study, presented at ACC 2021 scientific sessions, and simultaneously published in the Lancet. Researchers followed patients for 2 years and observed<a href="https://solaci.org/en/2021/05/20/acc-2021-host-exam-clopidogrel-vs-asa-monotherapy-post-dapt-in-pci-patients/" title="Read more" >...</a>

ACC 2021 | ATLANTIS: Apixaban post TAVI vs tratamiento estándar

ACC 2021 | ATLANTIS: Apixaban After TAVR vs. Standard of Care

Adding apixaban to the treatment of patients undergoing transcatheter aortic valve replacement (TAVR) was non-superior to standard antithrombotic treatment, according to the randomized ATLANTIS trial presented today at the American College of Cardiology (ACC) 2021 Congress. Given its easy indication and good safety profile, it could be an option to vitamin&nbsp;K antagonists for patients with<a href="https://solaci.org/en/2021/05/18/acc-2021-atlantis-apixaban-after-tavr-vs-standard-of-care/" title="Read more" >...</a>

ACC 2021 | TALOS-AMI: desescalar luego de 1 mes de ticagrelor a clopidogrel

ACC 2021 | TALOS-AMI: De-escalating from Ticagrelor to Clopidogrel after One Month

After one-month dual antiplatelet therapy (DAPT) with aspirin and ticagrelor, a net clinical benefit was observed when de-escalating to clopidogrel in acute myocardial infarction (AMI) patients treated with PCI.&nbsp; We have discussed the pros and cons of de-escalating from a potent antiplatelets Such as ticagrelor to clopidogrel since the TOPIC&nbsp;presented at EuroPCR in 2017. What<a href="https://solaci.org/en/2021/05/18/acc-2021-talos-ami-de-escalating-from-ticagrelor-to-clopidogrel-after-one-month/" title="Read more" >...</a>

doble antiagregacion plaquetaria sexo

Single or Dual Antiplatelet Therapy in Stroke or Transient Ischemic Attack?

Antiplatelet therapy is key to prevent thrombotic events after a transient ischemic attack (TIA) or ischemic stroke. The role of aspirin is well established in this scenario, but there is emerging evidence for a short period of dual antiplatelet therapy (DAPT). Now, can this strategy avoid recurrent strokes without paying a price in terms of<a href="https://solaci.org/en/2021/05/05/single-or-dual-antiplatelet-therapy-in-stroke-or-transient-ischemic-attack/" title="Read more" >...</a>

Xience Receives CE Mark for Short and Ultrashort DAPT Schemes

Dual antiplatelet therapy (DAPT) one month after angioplasty with Xience stent was approved in Europe for patients with high risk of bleeding. &nbsp; The CE Mark approval comes after studies Xience&nbsp;28 and Xience&nbsp;90 are published. Immediately after authorization, Abbot was fast to announce what they consider to be the shortest approved scheme with the most<a href="https://solaci.org/en/2021/04/26/xience-receives-ce-mark-for-short-and-ultrashort-dapt-schemes/" title="Read more" >...</a>

duración terapia de doble antiagregación plaquetaria

Dual Antiplatelet Therapy and TAVR: Obsolete Guidelines

The current guidelines recommend dual antiplatelet therapy (DAPT) 3 to 6 months after transcatheter aortic valve replacement (TAVI). Some recent data finally condensed in the present meta-analysis and recently published in JAHA happen to challenge these guidelines.&nbsp; Clinical studies that investigated single antiplatelet therapy versus DAPT until November 2020 were analyzed and divided according to<a href="https://solaci.org/en/2021/04/26/dual-antiplatelet-therapy-and-tavr-obsolete-guidelines/" title="Read more" >...</a>

Beta Bloqueantes

Post MI Betablockers for Good?

Patients receiving optimal medical treatment after MI do not seem to benefit from betablockers in the long term, provided they do not present cardiac failure or systolic function deterioration.&nbsp; This study looked into the cardio protection effect of betablockers (BB) after long term follow up in stable patients with no cardiac failure and a history<a href="https://solaci.org/en/2021/04/13/post-mi-betablockers-for-good/" title="Read more" >...</a>

Esquema corto y monoterapia, una práctica llena de evidencia

Short Therapy and Monotherapy, Plenty of Evidence

A short dual antiplatelet therapy (DAPT) of 1 to 3 months followed by P2Y12 inhibitor monotherapy after second generation drug eluting stent (DES) implantation is safer and as effective as the traditional scheme. The idea is clear, but why hasn’t aspirin monotherapy been tested as follow up? Is aspirin old fashioned? Are there physiopathological reasons<a href="https://solaci.org/en/2021/04/12/short-therapy-and-monotherapy-plenty-of-evidence/" title="Read more" >...</a>

Seguridad de combinar los nuevos anticoagulantes y la doble antiagregación

AAS vs Warfarin in Low Risk TAVR

We are still discussing the adequate antithrombotic scheme after transcatheter aortic valve replacement (TAVR). Additionally, we are treating a much wider array of patients ranging from low risk to inoperable.&nbsp; And there is yet one more important point: hypo-attenuated leaflet thickening diagnosed by CT. We are still unaware of the impact they have on device<a href="https://solaci.org/en/2021/03/15/aas-vs-warfarin-in-low-risk-tavr/" title="Read more" >...</a>

ticagrelor_enfermedad_vascular_periférica

Net Clinical Benefit of Long-Term Ticagrelor

Ticagrelor reduces ischemic risk in patients with a history of acute myocardial infarction, but it increases the risk of bleeding. Keeping a delicate balance is paramount when prescribing long-term ticagrelor to patients with a history of infarction. The PEGASUS-TIMI&nbsp;54 study randomized 21,162 patients with a history of infarction on a 1:1:1 ratio: some received ticagrelor<a href="https://solaci.org/en/2021/03/08/net-clinical-benefit-of-long-term-ticagrelor/" title="Read more" >...</a>

Top